The addition of PD-1/PD-L1 axis blockade to BRAF and MEK inhibition for advanced melanoma patients harboring mutations: a systematic review and meta-analysis BRAF
ABSTRACT Objectives: Immune-checkpoint inhibitors (ICI) and targeted-therapies (TT) have become standard options for BRAF-V600 metastatic melanomas (MM). Recently, randomized trials (RCT) addressed the efficacy of combined approaches, with conflicting results. We sought to evaluate efficacy and safety of first-line combination ICI and BRAF/MEK inhibitors (triplets) versus BRAF/MEKi (doublets). Methods: We performed a...
Clinical and sociodemographic profile of patients with cutaneous melanoma attended at an oncology referral hospital in Florianópolis between 2013 and 2017
ABSTRACT Introduction: Cutaneous melanoma is the most lethal skin cancer and its incidence has significantly increased in recent years. In particular, Florianópolis is the Brazilian capital with the highest incidence of the disease. Objective: To investigate the clinical and sociodemographic profile of patients with cutaneous melanoma treated at a public oncology referral...
ABSTRACT Penile melanoma is a rare event, responsible for less than 1.4% of penile cancers. In general, it is late diagnosed and the treatment is usually aggressive. The authors present a 66-year-old Caucasian man who had an ulcerated penile lesion for 1 year, diagnosed as melanoma after biopsy and treated...
ABSTRACT Introduction: Primary breast melanoma is a rare condition and most of cases are associated with melanoma overlying the skin of the breast or metastatic disease site. Primary breast parenchyma melanoma (PBPM) is extremely uncommon with only seven cases reported in the last four decades. Case report: A 44-year-old woman presented with...
